Skip to content

Zymeworks

US · ZYME #2828 by market cap Listed 2017
26.14 -0.72 -2.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership rose 2.7 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
101.12% +2.70pp
Institutions
253 -5
As of
2026/Q3 vs. prior period

Holder types

Hedge Fund53.85%
Mutual Fund31.87%
VC/PE Fund7.70%
Public Company6.43%
Individual/Insider1.38%
Private Company0.49%
Government Pension Fund0.41%
Bank/Investment Bank0.17%
Insurance Company0.16%
Other0.53%

Top holders as of 2026-10-21

EcoR1 Capital, LLC 33.28% · 22.97M sh
Rubric Capital Management LP 10.14% · 7.00M sh
BlackRock 6.10% · 4.21M sh
Perceptive Advisors LLC 6.06% · 4.18M sh
BVF Partners L.P. 5.29% · 3.65M sh
Morgan Stanley 4.69% · 3.24M sh
BNPP Asset Management Holding 2.36% · 1.63M sh
Vanguard Capital Management, LLC 2.26% · 1.56M sh
Assenagon Asset Management S.A. 2.18% · 1.51M sh
Nextech Invest Ltd. 1.61% · 1.11M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 31 buys · 4 sells

NameRoleStake
EcoR1 Capital, LLC -- 33.28%
Gregory Ciongoli Independent Director 0.71%
Kenneth Galbraith Chairperson & CEO 0.33%
Mark Hollywood Chief Operating Officer 0.19%
Paul Moore Chief Scientific Officer 0.07%
Adam Schayowitz Executive VP and Head of Research & Development 0.03%
Jeffrey T. Smith -- 0.03%
Troy Cox Former Independent Director 0.01%
Leone Patterson Former Executive VP and Chief Business & Financial Officer 0.00%
Brian Cherry Independent Director --
Nancy Davidson Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-08 Adam Schayowitz Executive VP and Head of Research & Development Derivative Exercise and Sale -13,832 $25.85
2026-10-08 Adam Schayowitz Executive VP and Head of Research & Development Derivative Exercise and Retained +23,205 --
2026-07-05 Mark Hollywood Chief Operating Officer Other Acquisition +939 $22.22
2026-05-12 Paul Schneider Executive Vice President Other Derivative Acquisition +119,000 --
2026-05-12 Paul Schneider Executive Vice President Other Derivative Acquisition +178,000 $24.57
2026-05-12 Paul Schneider Executive Vice President Initial Statement of Beneficial 0 --
2026-04-08 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +47,000 --
2026-04-08 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +70,000 $27.35
2026-04-08 Adam Schayowitz Executive VP and Head of Research & Development Other Derivative Acquisition +76,000 --
2026-04-08 Adam Schayowitz Executive VP and Head of Research & Development Initial Statement of Beneficial 0 --
2026-04-08 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +47,000 --
2026-04-08 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +70,000 $27.35
2026-04-08 Scott Platshon Executive VP & Chief Business Officer Other Derivative Acquisition +76,000 --
2026-04-08 Scott Platshon Executive VP & Chief Business Officer Initial Statement of Beneficial 0 --
2026-04-05 Kristin Stafford Chief Financial Officer Other Derivative Acquisition +169,000 --
2026-04-05 Kristin Stafford Chief Financial Officer Other Derivative Acquisition +178,000 $25.84
2026-03-31 Kristin Stafford Chief Financial Officer Initial Statement of Beneficial 0 --
2026-01-31 Sabeen Mekan Senior VP & Chief Medical Officer Initial Statement of Beneficial 0 --
2026-01-11 Kenneth Galbraith Chairperson & CEO Derivative Exercise and Sale -30,424 $22.67
2026-01-11 Kenneth Galbraith Chairperson & CEO Other Derivative Acquisition +144,000 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Zymeworks discussion 0 comments

Add a comment